肥厚型心肌病循环生物标志物的研究进展  

Circulating Biomarkers in Hypertrophic Cardiomyopathy

作　　者：牛志轩 艾孜在·艾来提 刘燕爽 田军磊 马骜 郑颖颖[1] NIU Zhixuan;Aizizai·Ailaiti;LIU Yanshuang;TIAN Junlei;MA Ao;ZHENG Yingying(Department of Cardiovascular Medicine,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,Xinjiang,China)

机构地区：[1]新疆医科大学第一附属医院心血管内科,新疆乌鲁木齐830000

出　　处：《心血管病学进展》2025年第1期29-32,共4页Advances in Cardiovascular Diseases

基　　金：2023年新疆医科大学校级大学生创新创业训练计划项目(X202310760128)。

摘　　要：肥厚型心肌病(HCM)是一种遗传性心脏病,其病理特征是心肌肥厚和心肌顺应性降低。血液中可测量的分子即生物标志物,在HCM的诊断、治疗和预测结果方面具有重要的指导作用。现综述多个与HCM相关的循环生物标志物,包括心肌壁拉伸、心肌坏死、心肌纤维化、炎症和细胞凋亡以及内皮功能障碍等关键病理过程中的分子。这些生物标志物可反映HCM的病情和进展,帮助临床医生进行诊断、指导治疗和预测结果。Hypertrophic cardiomyopathy(HCM)is a genetic heart disease characterized by cardiac hypertrophy and reduced cardiac compliance.The measurable molecules in the blood,namely biomarkers,play a crucial role in guiding the diagnosis,treatment,and predicting outcomes of HCM.This review highlights multiple circulating biomarkers associated with HCM,including molecules involved in key pathological processes such as myocardial wall stretching,myocardial necrosis,myocardial fibrosis,inflammation,cell apoptosis,and endothelial dysfunction.These biomarkers can reflect the condition and progression of HCM,assisting doctors in diagnosing diseases,guiding treatment,and predicting outcomes.

关 键 词：生物标志物 循环 肥厚型心肌病 诊断 预后 

分 类 号：R54[医药卫生—心血管疾病]